ARO CFB
Alternative Names: ARO-CFBLatest Information Update: 26 Apr 2024
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Antisense RNA
- Mechanism of Action Complement factor B expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II IgA nephropathy
Most Recent Events
- 22 Apr 2024 Phase-I/II clinical trials in IgA nephropathy (In adults, In the elderly) in New Zealand (SC) (NCT06209177)
- 18 Jan 2024 Arrowhead Pharmaceuticals plans a phase I/IIa trial for IgA nephropathy in March 2024 (SC) (NCT06209177)
- 21 Dec 2023 Preclinical trials in Kidney disorders in USA (unspecified) prior to December 2023